Evidence map›Paper›PMID 36193082›Full record

ArticleOxidative medicine and cellular longevity2022

Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment through Network Pharmacology and Bioinformatics Analysis.

Tao Han, Yiming Liu, Yutong Chen, Tingsong Chen, Yifan Li, Qiuhua Li, Mingfang Zhao

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Application of network pharmacology in synergistic action of Chinese herbal compounds.Theory in biosciences = Theorie in den Biowissenschaften · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tao HanDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110000, China.ORCID https://orcid.org/0000-0003-3814-8492
Yiming LiuLiaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110000, China.ORCID https://orcid.org/0000-0002-5289-3790
Yutong ChenThe General Hospital of Northern Theater Command Training Base for Graduate, China Medical University, Shenyang, Liaoning 110000, China.ORCID https://orcid.org/0000-0002-3516-9039
Tingsong ChenDepartment of Oncology, Shanghai Seventh People's Hospital, Shanghai 200137, China.ORCID https://orcid.org/0000-0001-9839-5191
Yifan LiThe First Department of Clinical Medicine, China Medical University, Shenyang, Liaoning 110000, China.ORCID https://orcid.org/0000-0002-8638-7378
Qiuhua LiLiaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110000, China.ORCID https://orcid.org/0000-0003-1561-1835
Mingfang ZhaoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110000, China.ORCID https://orcid.org/0000-0003-0183-144X
First Hospital of China Medical University · CNLiaoning University of Traditional Chinese Medicine · CNGeneral Hospital of Shenyang Military Region · CNSeventh People's Hospital of Shanghai · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrine and glycyrrhizin are representative active ingredients of traditional Chinese medicine (TCM) used in clinical practice. Studies have demonstrated that matrine has antitumor pharmacological effects and that glycyrrhizin protects liver function. However, the potential bioactive compounds and mechanisms remain unknown, as well as whether they have synergistic effects in killing cancer cells and protecting liver cells. To investigate the synergistic effects and mechanism of matrine combined with glycyrrhizin in hepatocellular carcinoma (HCC) treatment, we used both network pharmacology and bioinformatics analyses. First, the chemical gene interaction information of matrine and glycyrrhizin was obtained from the PubChem database. The pathogenic genes of HCC were accessed from five public databases. The RNA sequencing data and clinical information of HCC patients were downloaded from The Cancer Genome Atlas (TCGA). Next, the overlapping genes among the potential targets of matrine and glycyrrhizin and HCC-related targets were determined using bioinformatics analysis. We constructed the drug-target interaction network. Prognosis-associated genes were acquired through the univariate Cox regression model and Lasso-Cox regression model. The results were verified by the International Cancer Genome Consortium (ICGC) database. Finally, we predicted the immune function of the samples. The drug-target interaction network consisted of 10 matrine and glycyrrhizin targets. We selected a Lasso-Cox regression model consisting of 3 differentially expressed genes (DEGs) to predict the efficacy of the combination in HCC. Subsequently, we successfully predicted the overall survival of HCC patients using the constructed prognostic model and investigated the correlation of the immune response. Matrine and glycyrrhizin have synergistic effects on HCC. The model we obtained consisted of three drug-target genes by Lasso-Cox regression analysis. The model independently predicted the combined effect of matrine and glycyrrhizin in HCC treatment and OS, which will be helpful for guiding clinical treatment. The prognostic model was correlated with the immune cells and immune checkpoints of patients, which had an adjuvant effect on HCC immunotherapy. Matrine and glycyrrhizin can have therapeutic effects on HCC by promoting the production or enhancing the core gene activity in the drug network and improving the immune system function of patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAlkaloidsComputational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticGlycyrrhizic AcidHumansMatrinesNetwork PharmacologyQuinolizinesAlkaloidsGlycyrrhizic AcidMatrinesQuinolizines

Identifiers

PMID36193082
PMCPMC9526635
OpenAlexW4296782942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.